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Fluorescent labelling of these cells allowed the tracking of their
behaviour once placed into a 3D environment. Once recombined,
these two cell types coalesced to form spherical and elongated duct-
like structures. These structures comprised a layer of luminal cells
surrounded by myoepithelial cells. Confocal imaging of myoepithelial
and luminal markers revealed reconstitution of a bilayer structure
absolutely reflective of normal physiology.
This novel 3D model of the human breast duct presents a powerful
tool with which to dissect myoepithelial–luminal interactions in the
early stages of breast cancer, and will help uncover markers to predict
DCIS patients who will progress towards invasive breast cancer.
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Background Although rare, male breast cancer (MBC) is becoming
more common, yet remains understudied. Treatments are informed by
clinical studies conducted in women, based on assumptions that
underlying biology is the same, although evidence suggests this may
not be the case.
Methods A case-matched transcriptomic investigation of MBC and
female breast cancer was performed. Transcriptomic data was con-
firmed by qRT-PCR and biomarkers assessed immunohistochemically
on 477 MBC samples represented on tissue microarrays and related to
survival. MicroRNA (miR) expression was determined in a subset of
cases by RNA-seq.
Results Hierarchical clustering and Pathway Ingenuity Analysis
identified gender-specific gene expression patterns. Expression of
specific eIF transcripts was up-regulated in MBC, confirmed by qRT-
PCR. By immunohistochemistry, eIF4E and eIF5 were negatively
prognostic for overall survival (p = 0.012; HR = 1.77, 1.12–2.8 and
p = 0.033; HR = 1.68, 1.04–2.74, respectively). Effects on overall
survival remained independently prognostic upon multivariate anal-
ysis (eIF4E p = 0.05; HR 2.13 (1.0–4.6), eIF5 p = 0.04; HR 2.63
(1.04–6.65), respectively). Co-expression of eIF4E and -5
(p = 0.005; HR = 2.471, 1.280–4.770) also impacted on survival,
remaining so upon multivariate analysis (p = 0.002; HR 6.205,
1.99–19.30). miR analyses on a subset of MBC cases revealed
expression of 19 miRs which may regulate eIFs.
Conclusions Our findings support the notion that breast cancer is
different between genders. Overexpression of eIF4E and eIF5 sug-
gests these proteins could represent predictive biomarkers in MBC.
With mTOR inhibitors which target this pathway now in the clinic,
these biomarkers may represent new targets for therapeutic inter-
vention, although further independent validation is required.
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Chemotherapy resistance remains a major barrier to successful breast
cancer (BC) treatment. Therapies that inhibit drug efflux pumps to
overcome resistance have failed due to off-target side effects.
Manipulating tumour-specific pathways of drug efflux pump expres-
sion could target chemoresistance, whilst simultaneously overcoming
side effects. Our aim was to examine BC-specific, post-transcriptional
regulation of P-glycoprotein (ABCB1), an efflux pump long associ-
ated with chemoresistance.
First, we determined the ABCB1 untranslated regions (UTRs)
expressed in BC and established UTRs previously implicated as regu-
latory were broadly undetectable in primary BC samples or cell lines.
Next, we screened for potential microRNA regulators by in silico pre-
diction of binding to the expressed ABCB1 30UTR. The candidate pool
was refined using a BC cohort of 302 patients by eliminating micro-
RNAs not expressed or without an inverse correlation to ABCB1
mRNA. We further screened by examining microRNA (qPCR) and
P-glycoprotein (IHC) expression across a panel of matched normal
breast, DCIS and invasive BC tissues. P-glycoprotein was significantly
up-regulated across this progression, and onemicroRNA,miR-19b,was
significantly both down-regulated and negatively correlated with
P-glycoprotein, identifying it as the single candidate regulator.
Subsequent biochemical analyses found exogenous miR-19b
overexpression reduced P-glycoprotein protein expression and
enhanced intracellular epirubicin retention and associated cell death.
Surprisingly, mutation of the predicted miR-19b seed region did not
abrogate miR-19b-dependent regulation. In fact, sequential deletion
of the UTR identified a miR-19b-responsive region devoid of a miR-
19b seed site. In silico analysis revealed a consensus sequence for the
RNA-binding factor HuR. Both activity and expression of HuR were
essential for miR-19b loading to this non-canonical site.
Although miR-19b and HuR have been reported as putative
oncogenes, their role in breast cancer appears more equivocal and
targeting either could lead to chemoresistance.
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Introduction Breast cancer leptomeningeal metastasis (BCLM) is
particularly devastating, with a median survival of just 3–4 months.
Timely diagnosis is often challenged by low sensitivity of cere-
brospinal fluid (CSF) cytology. Further, translational progress is
hampered by the lack of in vivo BCLM models.
Methods CSF (B 10 mL) and plasma were collected from patients
with confirmed BCLM. Following protocol optimisation, cell-free
DNA (cfDNA) was extracted using Qiagen Circulating Nucleic Acid
Kit, quantified by Qubit fluorometer and fragment length assessed by
the Agilent Bioanalyzer. Primary human breast cancer cells were
injected intravenously into NSG mice. Mouse skull caps were for-
malin-fixed before dissecting out the meninges, which were stained
for human CK19 and lamin A/C, and whole-mounted for confocal
immunofluorescent imaging.
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